Form 4: Corcept CBO Granted 140,000 Stock Options

Corcept Therapeutics' Chief Business Officer, Gary Charles Robb, was granted 140,000 stock options with an exercise price of $35.70, vesting over four years.

Summary

• Gary Charles Robb, Chief Business Officer of Corcept Therapeutics Inc. (CORT), was granted 140,000 stock options.
• The options have an exercise price of $35.70 per share.
• The options begin vesting ratably in equal installments on each monthly anniversary of February 27, 2026, over a four-year period.
• Vesting is contingent upon Mr. Robb's continued service through each vesting date.
• The options expire on February 27, 2036.
• The underlying securities for these options are 140,000 shares of Common Stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine executive compensation event, reflecting standard practice for aligning management incentives with long-term company performance, thus having a neutral to slightly positive sentiment.

Positives

• The grant of stock options aligns the Chief Business Officer's financial incentives with the long-term performance and shareholder value of Corcept Therapeutics.
• This compensation structure is a common method for executive retention and motivation.

Negatives

• The exercise of these options in the future could lead to a dilution of existing shareholders' equity.

Risks

• The market price of Corcept Therapeutics (CORT) common stock may not exceed the exercise price of $35.70, rendering the options worthless.
• The options are subject to forfeiture if Gary Charles Robb's service terminates before the vesting dates.

Future Outlook

The vesting schedule of the stock options over a four-year period implies an expectation of continued service from the Chief Business Officer, aligning his long-term commitment with the company's future performance.

Industry Context

StockSavvy.ai notes that stock option grants are a common and widely accepted form of executive compensation within the biotechnology and pharmaceutical industries. This practice aims to align the interests of key management personnel with those of shareholders by incentivizing long-term company growth and stock price appreciation.

Comparison to Industry Standards

• Stock option grants with multi-year vesting schedules are a standard component of executive compensation packages across various industries, including biotech, to promote long-term commitment and performance.
• The four-year ratable monthly vesting schedule is typical for long-term incentive plans, comparable to practices seen at companies like Amgen or Gilead Sciences for their executive compensation structures.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also increased alignment of management's interests with shareholder value.
• Employees: Reflects standard executive compensation practices within the company and industry.

Next Steps

• Gary Charles Robb's continued service to Corcept Therapeutics is required for the options to vest according to the established schedule.

Key Dates

Recommendation

This Form 4 reports a routine grant of stock options to a Chief Business Officer as part of their compensation package. While it aligns management incentives, it does not provide new fundamental information to alter an investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

Corcept Therapeutics, CORT, Stock Options, Executive Compensation, Form 4, Insider Transaction, Gary Charles Robb, Chief Business Officer